Targeting PD-1/PD-L1, either alone or in combinati

Targeting PD-1/PD-L1, either alone or in combination, is a promising strategy for immune-related diseases.
___
"Low expression of PD-L1 has been implicated in the development and progression of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type 1 diabetes (T1D). In these diseases, reduced PD-L1 expression may contribute to a breakdown of immune tolerance, leading to an overactive immune response and tissue damage."
____
Crosstalk among cells via PD-1/PD-L1 is involved in physiological homeostasis and immune-related diseases.
•
Targeting PD-1/PD-L1, either alone or in combination, is a promising strategy for immune-related diseases.

" Meanwhile, PD-1/PD-L1 pathway has also been implicated in the pathogenesis of many immune-related diseases, such as autoimmune diseases, chronic infection diseases and adverse pregnancy outcomes, by regulating components of the innate and adaptive immune systems."

https://www.sciencedirect.com/science/article...2223013677
_____

Non-science brain --- given Leronlimab's safety, if mTNBC & CRC both show elevated PD-L1, do you start incorporating LL dosing on what would be a laundry list of diseases, like the ones above, outside of oncology ??